Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Curis Announces Three Presentations At ASH

Author: Benzinga Newsdesk | December 06, 2023 09:11am

Presentations

  • TakeAim Leukemia
    • Abstract Title: Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Acute Myeloid Leukemia Patients with FLT3 Mutation
    • Abstract Number: 2924
    • Program: Oral and Poster Abstracts
    • Session: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
    • Session Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PM



       
  • TakeAim Lymphoma
    • Abstract Title: Trial in Progress: An Open-Label Expansion Trial Evaluating the Safety, PK/PD, and Clinical Activity of Emavusertib (CA-4948) + Ibrutinib in R/R Primary CNS Lymphoma
    • Abstract Number: 3143
    • Program: Oral and Poster Abstracts
    • Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster II
    • Session Date and Time: Sunday, December 10, 2023, 6:00 PM-8:00 PM
    • Abstract Title: Takeaim Lymphoma: An Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies
    • Abstract Number: 4497
    • Program: Oral and Poster Abstracts
    • Session: 627. Aggressive Lymphomas: Clinical and Epidemiological: Poster III
    • Session Date and Time: Monday, December 11, 2023, 6:00 PM-8:00 PM

Posted In: CRIS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist